TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.
Brief Summary: Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days.

Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.


Options:
A: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Other: Ballistic Strength Training | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Physiotherapy | Intervention Type: OTHER; Name: Ballistic Strength Training; Assigned to Arm(s): Experimental | Intervention Type: OTHER; Name: Usual Care Physiotherapy; Assigned to Arm(s): Control
B: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: STARFISH | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STARFISH; Assigned to Arm(s): Intervention
D: Arm Label: ICoreDIST; Type: EXPERIMENTAL; Interventions: Procedure: ICoreDIST | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Intervention Type: PROCEDURE; Name: ICoreDIST; Assigned to Arm(s): ICoreDIST | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.
Brief Summary: Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days.

Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.


Options:
A: Arm Label: Early vertical positioning; Type: ACTIVE_COMPARATOR; Interventions: Other: Mobilization of stroke patients | Arm Label: Progressively vertical positioning; Type: ACTIVE_COMPARATOR; Interventions: Other: Mobilization of stroke patients | Intervention Type: OTHER; Name: Mobilization of stroke patients; Assigned to Arm(s): Early vertical positioning, Progressively vertical positioning
B: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy
C: Arm Label: The lying flat intervention; Type: EXPERIMENTAL; Interventions: Other: The lying flat (0°) head position for 24 hours | Arm Label: The sitting-up intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: The sitting-up (≥30°) head position for 24 hours | Intervention Type: OTHER; Name: The lying flat (0°) head position for 24 hours; Assigned to Arm(s): The lying flat intervention | Intervention Type: OTHER; Name: The sitting-up (≥30°) head position for 24 hours; Assigned to Arm(s): The sitting-up intervention
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.
Brief Summary: Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days.

Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.


Options:
A: Arm Label: Exercise recommendation; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise, Exercise recommendation
B: Arm Label: Intensive Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Walking | Arm Label: Conventional Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional Physical Therapy | Intervention Type: BEHAVIORAL; Name: Intensive Walking; Assigned to Arm(s): Intensive Walking | Intervention Type: BEHAVIORAL; Name: Conventional Physical Therapy; Assigned to Arm(s): Conventional Physical Therapy
C: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
D: Arm Label: Viscous Resistance & Abduction Loading; Type: EXPERIMENTAL; Interventions: Behavioral: Impairment-based robotic intervention for reaching function | Arm Label: Abduction Loading; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Impairment-based robotic intervention for reaching function | Intervention Type: BEHAVIORAL; Name: Impairment-based robotic intervention for reaching function; Assigned to Arm(s): Abduction Loading, Viscous Resistance & Abduction Loading

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Since docosahexaenoic acid (DHA) level in sperm membrane has been shown to be decreased in asthenozoospermic men, the investigators hypothesized that DHA supplementation may improve it. Furthermore, the investigators added vitamin E to it to protect its unsaturated bonds which are susceptible to oxidation and production of free oxygen radicals.


Options:
A: Arm Label: Folic acid and zinc supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 5 mg folic acid and 30 mg elemental zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 5 mg folic acid and 30 mg elemental zinc; Assigned to Arm(s): Folic acid and zinc supplementation | Intervention Type: DRUG; Name: Placebo Comparator: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: DHA plus vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin E, Dietary Supplement: DHA | Arm Label: VitaminE plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin E, Other: placebo | Arm Label: placebo plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: DHA plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA, Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin E; Assigned to Arm(s): DHA plus vitamin E, VitaminE plus placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA plus placebo, DHA plus vitamin E | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): DHA plus placebo, VitaminE plus placebo, placebo plus placebo
C: Arm Label: Zinc sulfate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: zinc sulfate | Arm Label: Healthy control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc sulfate; Assigned to Arm(s): Zinc sulfate
D: Arm Label: Impryl; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Impryl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Impryl; Assigned to Arm(s): Impryl | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Brief Summary: The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.


Options:
A: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin
B: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
D: Arm Label: Arm A: trabectedin + DOXIL; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: Arm B: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): Arm B: DOXIL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia
Brief Summary: Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator


Options:
A: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: M106 VNS Therapy System | Intervention Type: DEVICE; Name: M106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
B: Arm Label: Transcutaneous auricular vagal stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: Transcutaneous auricular non-vagal stimulation; Type: SHAM_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ear vagus nerve stimulator; Assigned to Arm(s): Transcutaneous auricular non-vagal stimulation, Transcutaneous auricular vagal stimulation
C: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: Model 106 VNS Therapy System | Intervention Type: DEVICE; Name: Model 106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Vagus Nerve Stimualtor | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Vagus Nerve Stimualtor | Intervention Type: DEVICE; Name: PINS Vagus Nerve Stimualtor; Assigned to Arm(s): Control, Experimental

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.

The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).


Options:
A: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets
C: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.

The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).


Options:
A: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
B: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
C: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer
Brief Summary: Recently results have shown that Bevacizumab is active both in monotherapy and in combination therapy in patients with ovarian cancer. One of our objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.


Options:
A: Arm Label: Arm 1: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Niraparib | Arm Label: Arm 2: Niraparib and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2: Niraparib and Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1: Niraparib, Arm 2: Niraparib and Bevacizumab
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vandetanib; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Paclitaxel & Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel & Carboplatin & Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial Comparing Robotic and Abdominal Surgery for High Risk Endometrial Cancer
Brief Summary: This study is intended to explore differences in oncologic and surgical safety between robotic assisted laparoscopy and conventional abdominal surgery for high risk endometrial cancer.


Options:
A: Arm Label: Robotic surgery; Type: EXPERIMENTAL; Interventions: Procedure: Robotic surgery | Arm Label: Abdominal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal surgery | Intervention Type: PROCEDURE; Name: Robotic surgery; Assigned to Arm(s): Robotic surgery | Intervention Type: PROCEDURE; Name: Abdominal surgery; Assigned to Arm(s): Abdominal surgery
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Laparoscopic Hysterectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot-assisted (Da Vinci®) laparoscopic hysterectomy | Intervention Type: PROCEDURE; Name: Conventional Laparoscopic Hysterectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Robot-assisted (Da Vinci®) laparoscopic hysterectomy; Assigned to Arm(s): 2
C: Arm Label: Laparoscopic Abdominal Sacrocolpopexy (LASC); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard laparoscopic abdominal sacrocolpopexy | Arm Label: Robotic Assisted Laparoscopic (RASC); Type: EXPERIMENTAL; Interventions: Procedure: Robotic assisted laparoscopic abdominal sacrocolpopexy | Intervention Type: PROCEDURE; Name: Robotic assisted laparoscopic abdominal sacrocolpopexy; Assigned to Arm(s): Robotic Assisted Laparoscopic (RASC) | Intervention Type: PROCEDURE; Name: Standard laparoscopic abdominal sacrocolpopexy; Assigned to Arm(s): Laparoscopic Abdominal Sacrocolpopexy (LASC)
D: Arm Label: Transperitoneal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transperitoneal laparoscopic aortic lymphadenectomy | Arm Label: Extraperitoneal; Type: EXPERIMENTAL; Interventions: Procedure: Extraperitoneal laparoscopic aortic lymphadenectomy | Intervention Type: PROCEDURE; Name: Transperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Transperitoneal | Intervention Type: PROCEDURE; Name: Extraperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Extraperitoneal

Answer: A